TNF and autoimmune polyendocrinopathy: The TNF-alpha inhibitor selected was Certolizumab, a TNF-α inhibitor that does not cross the placenta (IMPACT Study: IMProve Pregnancy in APS with Certolizumab Therapy, NCT03152058).